Table 2.
Transplant related complications of entire cohort and Class IIIB patients
| N = 55 (%)/Median range | N = 03 (%)/ median range Class IIIB | |
|---|---|---|
| TRM | None | None |
| Rejection | 1/55 (1.8%) | None |
| Primary | 0 | |
| Secondary | 1 | |
| Sinusoidal obstruction Syndrome (SOS) | 12/55 (21.8%) | 2/3 (66.7%) |
| Mild | 9 (75%) | 2 (100%) |
| Moderate | 2 (16.6%) | 0 |
| Severe | 1 (8.3%) | 0 |
| Infections | 14/55 (25.4%) | None |
| Viral = 1 | ||
| Bacterial = 11 | ||
| Fungal = 2 | ||
| Suspected Transplant Associated Microangiopathy | 13/55 (37.1) | None |
| Hemorrhagic cystitis | 3/55 (5.4%) | None |
| GVHD | ||
| Acute GvHD | 4/55 (7.2%) | 1/3 (33.3%) |
| Grade -1 | 2 | 0 |
| Grade-2 | 1 | 1 |
| Grade-3 | 1 | 0 |
| Grade -4 | 0 | 0 |
| Sites | Skin-3 | GIT-1 |
| Skin + GIT-1 | ||
| GIT- 1 | ||
| Chronic GvHD | 4/55 (7.2%) | None |
| Mild | 3 | |
| Moderate | 1 | |
| Severe | 0 | |
| Sites | Oral mucosa -1 | |
| Lung – 1 | ||
| Liver-1 | ||
| Skin + Oral mucosa-1 | ||
| Autoimmune cytopenia | 3/55 (5.4%) | None |
| Mucositis | 45/55 (81.8%) | 3/3 (100%) |
| Grade ½ | 34 (75.5%) | 2 (66.6%) |
| Grade 3 | 11 (24.4%) | 1 (33.3%) |
| CMV Reactivation | 17/55 (30.9%) | 1 (33.3%) |
| Required empirical treatment | 4 (23.5%) | 1 (100%) |
| Not required | 13 (76.4%) | |
| Hypertension due to cyclosporine | 26/55 (47.2%) | 1 (33.3%) |
| Mixed chimerism | 17 (30.9%) | 2 (3.6%) |
| Primary | 10 | 2 |
| Secondary | 7 | 0 |
| Level – I | 5 (29.4%) | 0 |
| Level – II | 9 (52.9%) | 2 (100%) |
| Level – III | 3 (17.6%) | 0 |
| Intervention done | 11 (64.7%) | |
| Immunosuppression boost | 6 (35.2%) | 2 (100%) |
| Immunosuppression tapering | 0 | 0 |
| DLI | 0 | 0 |